Angiotensin receptor-neprilysin inhibitors and cardiac remodeling

The aim of this study was to determine how sacubitril/valsartan compared with valsartan in an outpatient setting affects left ventricular remodeling in heart failure with reduced ejection fraction and functional (or secondary) mitral regurgitation (SMR) due to the effect of dual inhibition of the re...

Full description

Bibliographic Details
Main Authors: A.S. Ryazanov, E.V. Shikh, M.V. Makarovskaya, A.A. Kudryavtsev
Format: Article
Language:English
Published: Associação Brasileira de Divulgação Científica 2023-04-01
Series:Brazilian Journal of Medical and Biological Research
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2023000100625&tlng=en
_version_ 1797849065893920768
author A.S. Ryazanov
E.V. Shikh
M.V. Makarovskaya
A.A. Kudryavtsev
author_facet A.S. Ryazanov
E.V. Shikh
M.V. Makarovskaya
A.A. Kudryavtsev
author_sort A.S. Ryazanov
collection DOAJ
description The aim of this study was to determine how sacubitril/valsartan compared with valsartan in an outpatient setting affects left ventricular remodeling in heart failure with reduced ejection fraction and functional (or secondary) mitral regurgitation (SMR) due to the effect of dual inhibition of the renin-angiotensin system and neprilysin. The outpatient study included 90 patients with chronic SMR who were followed up for 12 months. They received sacubitril/valsartan or valsartan instead of the more commonly used angiotensin-converting enzyme inhibitor enalapril for heart failure, in addition to standard medical therapy for heart failure. The difference in NT-proBNP change between groups was the primary endpoint. Changes in effective regurgitation orifice area, left ventricular ejection fraction, left ventricular end-systolic and end-diastolic volume indices, left atrial volume index, E/e' index, and exercise tolerance on the 6-minute walk test were secondary endpoints. In the treatment efficacy analysis, NT-proBNP levels decreased significantly by 37% in the sacubitril/valsartan group and by 11% in the valsartan group (P<0.001). Ejection fraction and exercise tolerance (increase in walking distance in the 6-min test) increased in the sacubitril/valsartan group (P<0.05). Also, in this group, the effective area of the regurgitation orifice, the left atrial volume index, the E/e' index, and the indices of the end-systolic and end-diastolic volume of the left ventricle (P<0.05) decreased more pronouncedly. Compared with valsartan, treatment with sacubitril/valsartan led to a significant improvement in cardiac remodeling in patients with SMR and heart failure with reduced ejection fraction.
first_indexed 2024-04-09T18:37:53Z
format Article
id doaj.art-d4ed1835861f46f4ab4cac63947ca21f
institution Directory Open Access Journal
issn 1414-431X
language English
last_indexed 2024-04-09T18:37:53Z
publishDate 2023-04-01
publisher Associação Brasileira de Divulgação Científica
record_format Article
series Brazilian Journal of Medical and Biological Research
spelling doaj.art-d4ed1835861f46f4ab4cac63947ca21f2023-04-11T07:31:29ZengAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research1414-431X2023-04-015610.1590/1414-431x2023e12616Angiotensin receptor-neprilysin inhibitors and cardiac remodelingA.S. Ryazanovhttps://orcid.org/0000-0001-9574-6021E.V. Shikhhttps://orcid.org/0000-0001-6589-7654M.V. Makarovskayahttps://orcid.org/0000-0002-2313-2159A.A. Kudryavtsevhttps://orcid.org/0000-0001-8294-5136The aim of this study was to determine how sacubitril/valsartan compared with valsartan in an outpatient setting affects left ventricular remodeling in heart failure with reduced ejection fraction and functional (or secondary) mitral regurgitation (SMR) due to the effect of dual inhibition of the renin-angiotensin system and neprilysin. The outpatient study included 90 patients with chronic SMR who were followed up for 12 months. They received sacubitril/valsartan or valsartan instead of the more commonly used angiotensin-converting enzyme inhibitor enalapril for heart failure, in addition to standard medical therapy for heart failure. The difference in NT-proBNP change between groups was the primary endpoint. Changes in effective regurgitation orifice area, left ventricular ejection fraction, left ventricular end-systolic and end-diastolic volume indices, left atrial volume index, E/e' index, and exercise tolerance on the 6-minute walk test were secondary endpoints. In the treatment efficacy analysis, NT-proBNP levels decreased significantly by 37% in the sacubitril/valsartan group and by 11% in the valsartan group (P<0.001). Ejection fraction and exercise tolerance (increase in walking distance in the 6-min test) increased in the sacubitril/valsartan group (P<0.05). Also, in this group, the effective area of the regurgitation orifice, the left atrial volume index, the E/e' index, and the indices of the end-systolic and end-diastolic volume of the left ventricle (P<0.05) decreased more pronouncedly. Compared with valsartan, treatment with sacubitril/valsartan led to a significant improvement in cardiac remodeling in patients with SMR and heart failure with reduced ejection fraction.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2023000100625&tlng=enHeart failureCardiac remodelingNeprilysinAngiotensin receptor blockers
spellingShingle A.S. Ryazanov
E.V. Shikh
M.V. Makarovskaya
A.A. Kudryavtsev
Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
Brazilian Journal of Medical and Biological Research
Heart failure
Cardiac remodeling
Neprilysin
Angiotensin receptor blockers
title Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
title_full Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
title_fullStr Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
title_full_unstemmed Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
title_short Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
title_sort angiotensin receptor neprilysin inhibitors and cardiac remodeling
topic Heart failure
Cardiac remodeling
Neprilysin
Angiotensin receptor blockers
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2023000100625&tlng=en
work_keys_str_mv AT asryazanov angiotensinreceptorneprilysininhibitorsandcardiacremodeling
AT evshikh angiotensinreceptorneprilysininhibitorsandcardiacremodeling
AT mvmakarovskaya angiotensinreceptorneprilysininhibitorsandcardiacremodeling
AT aakudryavtsev angiotensinreceptorneprilysininhibitorsandcardiacremodeling